Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial
E Segarra Martínez(Hospital Clínic de Barcelona), V. Estrada, Markella V. Zanni(Harvard University), Heather J. Ribaudo(Cancer Research And Biostatistics), Carl J. Fichtenbaum(Cancer Research And Biostatistics), Sarah M Chu(Harvard University), Risa M. Hoffman(University of California, Los Angeles), Craig A. Sponseller, Suman Srinivasa(Massachusetts General Hospital), Sylvie Trottier, Carlos Malvestutto(The Ohio State University Wexner Medical Center), Damocles Patrice Severe, Sara McCallum(Cancer Research And Biostatistics), Lerato Mohapi, Judith A. Aberg(Icahn School of Medicine at Mount Sinai), Luiz Carlos Pereira, Marcus Vinícius Guimarães Lacerda, Esper Georges Kallas, Julian Falutz, Alex B Lu(Harvard University), Jorge A. Pinto, M Lu(Harvard University), Gerald S Bloomfield(Duke University), Judith S Currier(University of California, Los Angeles), Maya Watanabe(Cancer Research And Biostatistics), Pamela S Douglas(Duke University), Anton Pozniak(Chelsea and Westminster Hospital), Saate S Shakil(University of California, Los Angeles), Steven K Grinspoon(Harvard University), Beatriz Grinsztejn, Graham H.R. Smith, Breno Riegel Santos, Brian Conway, Marek Smieja, Ayotunde Omoz-Oarhe, Vidya Mave, Javier Antonio Valencia, Sharlaa Badal-Faesen, Vanessa Rouzier, Umesh Gangharam Lalloo, Sharon Lynn Walmsley, Mauro Schechter, Nagalingeswaran Kumarasamy, Esau Custodio Joao, Jose Henrique da Silva Pilotto, Jose Valdez Ramalho Madruga, Mark F. Cotton, Rodney Dawson(University of Cape Town), Esteban Martínez(Hospital Clínic de Barcelona), Javier R. Lama(Asociación Civil Impacta Salud y Educación)
Cited by 1
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Antiretroviral Treatment of Adult HIV Infection
|JAMA|2010|725
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661